Completed
PHASE1
INTERVENTIONAL
NCT05804162
A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The study tests if treatment with cagrilintide delays the transmission of electrical signals in the heart compared to treatment with placebo. To confirm the sensitivity of the methodology, the drug moxifloxacin is also compared to a placebo in 2 treatment arms. Cagrilintide is being developed for the treatment of obesity and weight management. Moxifloxacin is an approved antibiotic for the treatment of bacterial illnesses. The study lasts for up to 17 weeks for each participant.
Interventions
Name:
Cagrilintide
Type:
DRUG
Description:
Participants will receive 0.6 mg subcutaneous injections of cagrilintide once weekly and the dose will be then escalated once in 2 weeks for 8 weeks until the target maintenance dose of 4.5 mg is reached followed by a 38-day post-treatment period.
Name:
Cagrilintide Placebo
Type:
DRUG
Description:
Participants will receive cagrilintide placebo subcutaneously once weekly.
Name:
Moxifloxacin
Type:
DRUG
Description:
Partcipants will receive a single dose of moxifloxacin orally.
Name:
Moxifloxacin Placebo
Type:
DRUG
Description:
Partcipants will receive a single dose of moxifloxacin orally.
Primary Outcomes
Measure:
Change From Baseline in Fridericia Heart Rate Corrected QT Interval (QTcF) At 12, 24, 48 and 72 Hours Post-Second Dose of Cagrilintide/Cagrilintide Placebo at the 4.5 mg Dose Level
TimeFrame:
From pre-last dose on Day 52 to 12, 24, 48 and 72 hours post-last dose on Day 55
Description:
Measured in millisecond
Trial Information
NCT ID
NCT05804162
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025